Radiotracer-based strategies to image angiogenesis

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 3, 2003, Pages 189-199

  Haubner, R ^a   Wester, H J ^a   Weber, W A ^a   Schwaiger, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fibronectins; Matrix metalloproteinases; Neovascularization, pathologic; Radionuclide imaging; Tomography, emission computed; Tomography, emission computed, single photon; Vitronectin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ARGINYLGLYCYLASPARTIC ACID Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CYSTEINYLTHREONYLTHREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEUCYLCYSTE INE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHAVBETA3 INTEGRIN ANTAGONIST; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CGS 27023A; CILENGITIDE; CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO PHENYLALANYLTYROSINE) I 125; CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO TYROSYLVALINE) I 125; CYSTEINYLTHREONYLTHREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEU C YLCYSTEINE; ENDOSTATIN; FIBRONECTIN; GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; GLUCO ARGINYLGLYCYLASPARTIC ACID I 125; GLYCOPROTEIN; ILOMASTAT; INTEGRIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATRIX PROTEIN; MONOCLONAL ANTIBODY LM 609; PENTETATE ARGINYLGLYCYLASPARTIC ACID IN 111; PROTEIN INHIBITOR; SEMAXANIB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TANOMASTAT; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; CANCER; CANCER RESEARCH; CELL ACTIVATION; CELL MIGRATION; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG ACCUMULATION; DRUG CLASSIFICATION; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NON INVASIVE MEASUREMENT; NONHUMAN; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT PLANNING; TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; INTEGRIN ALPHAVBETA3; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOISOTOPES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0142074845     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: A new potential anticancer therapeutic strategy. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:241-53.
2. Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T et al. Angiogenesis factors. Intern Med 2001;40:565-72.
3. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM et al. Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 2001;28:94-104.
4. Richard DE, Berra E, Pouyssegur J. Angiogenesis: How a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266:718-22.
5. Harris AL. Hypoxia: A key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
7. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: From basic research to clinical trials. Crit Rev Oncol Hematol 2000;34:89-110.
8. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-17.
9. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
10. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001;33:960-70.
11. Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res 1999;32:501-10.
12. Eliceiri BP, Cheresh DA. Role of αv integrins during angiogenesis. Cancer J Sci Am 2000;6:S245-9.
13. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
14. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001;6:1005-24.
15. Rosen LS. Inhibitors of the vascular endothelial growth factor receptor. Hematol Oncol Clin North Am 2002;16:1173-87.
16. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
17. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001;7:S134-8.
18. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
19. Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger K, Young V et al. Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2002;20:431-7.
20. Heath EI, Grochow LB. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000;59:1043-55.
21. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22.
22. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int J Cancer 2000;87:716-23.
23. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J et al. Pilot study of vitaxin - An angiogenesis inhibitor in patients with advanced leiomyosarcomas. Cancer 2001;92:1347-8.
24. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.
25. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
26. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000;21:505-15.
27. Weber WA, Haubner R, Vabuliene E, Kuhnast B, Wester HJ, Schwaiger M. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med 2001;45:179-82.
28. Hynes R. Molecular biology of fibronectin. Annu Rev Cell Biol 1985;1:67-90.
29. Castellani P, Dorcaratto A, Pau A, Nicola M, Siri A, Gasparetto B et al. The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas. Acta Neurochir 2000;142:277-82.
30. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997;15:1271-5.
31. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999;94:192-8.
32. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001;28:534-9.
33. Curran S, Murray GI. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30.
34. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
35. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
36. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001;6:478-82.
37. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metastasis 1994;14:246-58.
38. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996;87:602-11.
39. Koivunen E, Arap W, Valtanen H, Rainisalo A, Median OP, Heikkila P et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
40. Kuhnast B, Haubner R, Wester H-J, Bodenstein C, Schwaiger M, Weber WA. In vivo evaluation of a labeled decapeptide to image gelatinase activity. J Nucl Med 2002;43 Suppl:370P.
41. 64Cu-Dota-CTTHWGFTLC, a selective gelatinase inhibitor for tumor imaging. J Nucl Med 2002;43 Suppl:277P.
42. 18F-labeled matrix metalloproteinase-2 inhibitor for cancer imaging by PET. J Nucl Med 2002;43 Suppl:364P.
43. 11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J Labelled Cpd Radiopharm 2002;45:449-70.
44. 11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002;29:761-70.
45. Kuhnast B, Bodenstein C, Wester HJ, Haubner R, Schwaiger M, Weber W. Carbon-11 labelling of a N-sulfonylamino acid derivative for MMP-2 and MMP-9 imaging. Eur J Nucl Med 2002;29 Suppl 1:S76.
46. Kuhnast B, Bodenstein C, Wester HJ, Weber WA. Carbon-11 labelling of a N-sulfonylamino acid derivative: A potential tracer for MMP-2 and MMP-9 imaging. J Label Compd Radiopharmacol 2003;46:539-53.
47. Tamura Y, Watanabe F, Nakatani T et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem 1998;41:640-9.
48. Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996;3:881-5.
49. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7.
50. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
51. Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997;36:1374-89.
52. 3 integrin antagonists: Chemical and structural requirements for activity and selectivity. Mini Rev Med Chem 2002;2:531-42.
53. Kerr JS, Slee AM, Mousa SA. Small molecule α(v) integrin antagonists: Novel anticancer agents. Expert Opin Investig Drugs 2000;9:1271-9.
54. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50-4.
55. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent antiadhesive RGD peptides. Eur J Biochem 1992;210:911-21.
56. 3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 1999;40:1061-71.
57. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
58. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
59. 3 integrin. J Nucl Med 2002;43 Suppl:89P.
60. Haubner R, Wester HJ, Weber WA, Linke W, Bodenstein C, Kessler H et al. Improved pharmacokinetics of [F-18]RGD-peptides by serine-conjugation. J Label Radiopharmacol 2001;44 Suppl 1:S157-9.
61. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M et al. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta(3) integrin related tumor imaging. Nucl Med Biol 2003;30:1-9.
62. 99mTc, Re-188- and Y-90-labeled αvβ3 antagonists: Promising tracer for tumor-induced angiogenesis. J Nucl Med 2000;41:41P.
63. 99mTc-labelled cyclic RGD-peptide for imaging the αvβ3 expression. Nucl Med Biol. In press 2003.
64. Van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186-98.
65. 3 integrin for tumor imaging. Bioconjug Chem 2002;13:561-70.
66. Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, Edwards DS et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor imaging. Cancer Biother Radiopharm 2002;17:641-6.
67. 3 integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
68. 3 integrin expression. Eur J Nucl Med 2001;28 Suppl:1175.
69. 3 expression (German). Nucl Med 2003;42:A55.
70. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.
71. Pichler B, Braumueller H, Haubner R, Sakrauski AK, Kneilling M, Senekowitsch-Schmidtke R et al. Monitoring of cellular immunotherapy in RIP1-Tag2 transgenic mice with radiolabeled RGD-peptides. J Nucl Med 2002;43 Suppl:122P.
72. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998;25:1383-9.
73. Fauchere JL, Morris AD, Thurieau C, Simonet S, Verbeuren TJ, Kieffer N. Modulation of the activity and assessment of the receptor selectivity in a series of new RGD-containing peptides. Int J Pept Protein Res 1993;42:440-4.
74. 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 2002;29:754-9.
75. Bock M, Haubner R, Senekowitsch-Schmidtke R, Kessler H, Stöcklin G, Schwaiger M et al. Homo- and heteromultimeric ligandsystems: Potential tracer for tumor imaging and endoradiotherapy (German). Nucl Med 1999;38 Suppl:A44.
76. De Jong M, Van Hagen PM, Breeman WA, Bernard HF, Schaar M, Van Gameren A et al. Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy. J Nucl Med 2000;41 Suppl:232P.
77. 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 2001;12:559-68.
78. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem 2001;12:624-9.
79. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD-peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chem Eur J 2003;9:2717-25.
80. Poethko T, Thumshirn G, Hersel U, Rau F, Haubner R, Schwaiger M et al. Improved tumor uptake, tumor retention and tumor/background ratios of pegylated RGD-multimers. J Nucl Med 2003;44 (Suppl):46P.
81. Horton MA. Integrin antagonists as inhibitors of bone resorption: Implications for. Proc Nutr Soc 2001;60:275-81.
82. Tucker GC. Inhibitors of integrins. Curr Opin Pharmacol 2002;2:394-402.
83. 3 integrin antagonists. J Med Chem 2001;44:1938-50.